Participated · Equity · Jul 2026

DigiSchool develops and operates digital education services and platforms for learners and educational markets. The company intends to expand both organically and through acquisitions to broaden its service offering and market reach. Its platform technology has received targeted public support from Bpifrance, including a €600,000 prêt participatif and a €500,000 zero-interest loan for innovation. DigiSchool has previously benefited from innovation aids and earlier seed-stage participative financing and was formerly associated with Kreactive. The recent €3 million fundraising with Groupe Turenne Capital, Alto Invest and historical investors is intended to finance its external and internal growth initiatives. The company is headquartered in Lyon.

Participated · Equity · Feb 2019

OssDsign develops and markets next-generation bone replacement products based on advanced material science, including patient-specific cranial implants and an off-the-shelf synthetic bone graft for spine surgeries. The company supports the body’s own healing capabilities to improve clinical outcomes across multiple orthopedic indications. OssDsign has a strong commercial presence in the US, Europe and selected Asian countries and its share is traded on Nasdaq First North Growth Market in Stockholm, Sweden. The company is pursuing expansion of its product portfolio and advancement of clinical programs. Recent financing was explicitly intended to fund its efforts to build a global bone graft business and accelerate growth in the US. The company is positioned to use the strengthened financial base to support commercialization and clinical development. OssDsign is a portfolio company of Karolinska Development that develops medical products for craniomaxillofacial indications and is broadening its focus to orthobiologics and spinal surgery. In early March the company presented a new corporate strategy, ASCENT25, intended to accelerate growth, value creation and innovation and achieve positive cash flow by 2025. To support that strategy OssDsign completed a rights issue with preferential rights for existing shareholders, which was oversubscribed. The board exercised an over‑allotment option to carry out a directed new issue, bringing total gross proceeds to SEK 270 million excluding transaction costs. The fundraising outcome is expected to enable strategic investments to expand the product portfolio and sales into additional orthopedic market segments. Karolinska Development, a long‑term investor, subscribed for its pro rata share in the new issue. OssDsign develops and sells regenerative implant solutions intended to improve healing of bone defects. The company intends to use new proceeds to expand sales in Europe and the US and to enter new markets. OssDsign is preparing for a market introduction in Japan, running pre-marketing activities in parallel with the regulatory process and with ethical committee approval in place for surgeons to start building experience. The company is preparing for a listing on Nasdaq First North in 2019, with Erik Penser Bank acting as financial advisor. Karolinska Development is a major backer, holding 25% on a fully diluted basis. The recent financing is intended to support commercialization and geographic expansion rather than research-stage development. OssDsign develops regenerative implants to improve healing of bone defects and deficits in skull, facial and other types of surgery. Its product portfolio includes Craniomosaic for cranioplasty and Sculpter for facial reconstruction. The products are currently available in Germany, the United Kingdom and the Nordic countries, with further expansion in Europe scheduled for 2016. The company is working with regulatory authorities to expand access in new key markets and expects clearance in the US in 2016. Led by CEO Anders Lundqvist, OssDsign plans to use new funding to accelerate market expansion of its craniofacial implant line. The company recently completed an equity financing to support these plans. OssDsign develops patient-specific bioceramic implants for bone healing, starting with its OssDsign Cranio PSI product for skull reconstruction. The company has a registration certificate for production and sales of patient-specific implants and reports very positive results in treated patients to date. After completing a SEK 13.7m rights issue, OssDsign has initiated a clinical multi-center study evaluating clinical outcomes, quality of life, and health economics; first patients have been treated at Karolinska University Hospital. The company is developing a new bioceramic material with a chemical composition similar to bone and aims to transform that technology into differentiated products for bone replacement. Its strategy is to build a niche orthopedics company beginning with sales in skull surgery and extend applications to other areas such as fracture healing. The market for bone replacement products was reported as worth EUR 1bn in 2012.

Led · Equity · Jun 2018

Crème de la Crème is a Paris-based curated freelance marketplace that connects a vetted community of freelancers in tech, data, design, marketing and communication to more than 5,000 clients. It combines a freelancer-matching algorithm with manual in-house curation; clients are assigned an account manager and typically receive up to five quotes within 48 hours. For larger projects the platform’s selection experts can form teams of freelancers. The company counts returning customers such as L'Oreal, LinkedIn, Airbnb and BNP Paribas, and reports over 3,000 UK freelancers and more than 500 British companies using the service. Crème de la Crème plans to use new funding to expand in the UK and will release a mobile app for freelancers in September to manage projects, invoicing and community engagement.

Participated · Equity · Jan 2018

Yousign is a SaaS e-signature provider and certification authority that complies with Europe’s eIDAS framework and archives documents via a partnership with Arkhineo. The product offers templates, approval workflows, reminders, strong authentication and timestamping to ensure legally binding signatures. The company targets SMBs that are not yet using e-signature tools and aims to be a Europe-first alternative to U.S. incumbents. Yousign says customers can sign their first documents within an hour and charges via subscription. It has 6,000 clients today and plans to reach 50,000 European SMBs by 2024, which it projects would represent about $85 million in ARR (€70 million). The company grew headcount from 35 to 120 in 2020 and plans to hire 150 more employees over the next 18 months. Yousign is a French e-signature provider offering document upload, automated emails and notifications, legally binding signatures, archiving, templates, and an API. The company is available in France, Germany, the U.K. and Spain and aims to build a pan‑European e-signature solution. eFounders has partnered with and invested in Yousign, buying out existing investors for several millions of euros to clean the cap table. In the transaction eFounders acquired around 50% of the company through an SPV it controls, while holding 25% directly and with 25% held by investors in the eFounders eClub. Founders reportedly still retain the majority of shares despite the transaction. The company faces the challenge of Europe’s fragmented market and must convince users in different countries to switch to its solution. Yousign develops electronic-signature solutions for signing agreements and contracts and serves roughly 1,500 customers. The company raised €3 million in new funding to bolster its presence around Europe and to hire additional staff. The funds will be used to hire about twenty people this year across technical, sales and marketing roles. Yousign plans to step up development for large-enterprise customers with a new product called Yousign Corporate. Management says the financing will help structure the company for a planned European launch at the end of the year. The article notes that e-signatures have been officially recognized in France since 2000, although adoption among companies remains uneven.

Participated · Equity · Mar 2017

Nosopharm is a biotechnology company based in Lyon, France, focused on researching and developing new anti-infective drugs. Founded in 2009 and led by CEO Philippe Villain-Guillot, it discovered and developed NOSO-502, a first-in-class antibiotic from the Odilorhabdins class for multidrug-resistant hospital-acquired infections. The company has expertise in discovering natural bioactive products from the Xenorhabdus and Photorhabdus microbial genera and in the medicinal chemistry of Odilorhabdins. It has a staff of eight. Nosopharm received a €1.0M interest-free loan from Bpifrance to fund CMC development and regulatory preclinical research for NOSO-502 and to support a clinical trial authorization submission in 2019. The company planned to begin first-in-human trials in 2020. To date it has raised €4.3M in private equity and received €3.8M in grants from Bpifrance, IMI, DGA, Region Languedoc-Roussillon and FEDER. Nosopharm focuses on discovery and development of new antibacterial molecules, notably NOSO-95179, an odilorhabdin-class antibiotic for multidrug-resistant hospital-acquired infections. The company has expertise in discovering natural bioactive products from Xenorhabdus and Photorhabdus genera and in the medicinal chemistry of odilorhabdins. It intends to use recent funding to accelerate regulatory preclinical development of NOSO-95179, which targets Enterobacteriaceae, a WHO priority pathogen. Nosopharm expected to start first-in-man studies in 2019. The company is led by Philippe Villain-Guillot and has a staff of seven. Financially, Nosopharm has combined private equity and grant support alongside the new funding to advance its lead candidate.